Bacil Pharma's board has approved a rights issue of up to ₹50 crore and a ₹45 crore increase in authorised share capital. Two independent directors have resigned.
Bacil Pharma Plans Rights Issue Up To ₹50 Crore
Bacil Pharma aims to raise up to ₹50 crore through a rights issue of equity shares. The company's board has also approved a ₹45 crore increase in its authorised share capital, bringing the total to ₹65 crore.
Reader Takeaway: Capital raise signals growth potential but brings dilution and governance watch.
What just happened
The Board of Directors of Bacil Pharma Limited has given the go-ahead for a rights issue to raise funds not exceeding ₹50 crore. To facilitate this, the company will also increase its authorised share capital by ₹45 crore, taking the total to ₹65 crore.
Why this matters
This capital infusion could fuel business expansion or operational improvements. However, a rights issue typically results in equity dilution, potentially impacting earnings per share. The timing and terms of the issue, including the price and ratio, will be crucial for existing shareholders.
The backstory
Bacil Pharma operates in the pharmaceutical sector. This rights issue marks a significant move to bolster its financial resources.
What changes now
A Right Issue Committee has been formed to manage the process. Intermediaries like Purva Sharegistry (India) Private Limited (Registrar), Axis Bank Limited (Banker), and Acuite Ratings & Research Limited (Monitoring Agency) have been appointed.
Risks to watch
Two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, have resigned. Investors should monitor the reasons for these resignations and their implications for corporate governance. Equity dilution is another key risk.
Peer comparison
(No peer comparison data available in the filing).
Context metrics (time-bound)
- Rights Issue Amount: Up to ₹50 crore
- Authorised Capital Increase: ₹45 crore
- New Total Authorised Capital: ₹65 crore
- Face Value Per Share: ₹10
What to track next
Investors should look out for the announcement of the specific issue price, the rights entitlement ratio, and the record date. Monitoring the company's strategic use of the raised funds and any further developments regarding board composition will also be important.